KEY POINTS
- This Italian National Health Service-perspective cost-utility analysis compared neoadjuvant chemoradiotherapy followed by external-beam RT boost versus contact X-ray brachytherapy (CXB/Papillon) boost in patients resembling the randomized phase III OPERA population. Eligible disease was operable cT2–T3a/b low or mid-low rectal adenocarcinoma smaller than 5 cm, without extensive nodal or other high-risk features.
- The modeled treatment pathways used 45 Gy in 25 fractions with capecitabine, followed by either EBRT boost 9 Gy in five fractions or CXB boost 90 Gy in three fractions. Response-adapted watch-and-wait, local excision or radical surgery was incorporated into the modeled subsequent management.
- Clinical effectiveness inputs came from OPERA, where three-year organ preservation was 81% with CXB versus 59% with EBRT boost, an absolute improvement of 22 percentage points. The advantage was particularly pronounced for tumors smaller than 3 cm, with organ preservation of 97% versus 63%; for tumors at least 3 cm, rates were 68% versus 55%.
- In the three-year economic base case, estimated per-patient costs were €20,337 with CXB versus €22,043 with EBRT boost, yielding a modeled saving of approximately €1,705. Estimated quality-adjusted survival was 2.391 versus 2.340 QALYs, corresponding to an incremental gain of approximately 0.052 QALYs.
- The model predicted a reduction in permanent stoma probability from 18.5% with EBRT boost to 8.5% with CXB, an absolute decrease of approximately 10 percentage points. In an illustrative 100-patient scenario, replacing EBRT boost with CXB was projected to preserve 22 additional rectums, avoid approximately 10 permanent stomas, and reduce modeled three-year expenditure by approximately €170,500.
- Probabilistic sensitivity analysis estimated a mean incremental cost of −€1,626 and a mean QALY gain of 0.048 with CXB. The CXB strategy was both less costly and more effective in 81.4% of simulations, with a 95.1% probability of cost-effectiveness at €25,000/QALY.
- CXB was associated with a substantial increase in late mild rectal bleeding (62.7% vs 11.6% in OPERA), an important clinical trade-off included in the model. The economic analysis relied on Italian reimbursement tariffs rather than observed patient-level hospital costs, assumed established CXB infrastructure, and was sensitive to program overhead, equipment costs, annual patient volume and the magnitude of organ-preservation benefit.
CLINICAL TAKEAWAY
In appropriately selected patients with early low rectal cancer, the greater organ preservation achieved with CXB in OPERA may offset additional procedure costs through fewer radical operations and permanent stomas. However, the apparent economic advantage is model-based and dependent on established infrastructure, local reimbursement and surveillance capacity, so it should not be interpreted as proof that introducing a new CXB program will save money in every healthcare system.